Eyepoint Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2025: 51.43%

Eyepoint Pharmaceuticals Inc (EYPT) has an Asset Resilience Ratio of 51.43% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EYPT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$129.44 Million

Cash + Short-term Investments

Total Assets

$251.69 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2009–2024)

This chart shows how Eyepoint Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Eyepoint Pharmaceuticals Inc balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Eyepoint Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read EYPT total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$129.44 Million	51.43%
Total Liquid Assets	$129.44 Million	51.43%

Asset Resilience Insights

Very High Liquidity: Eyepoint Pharmaceuticals Inc maintains exceptional liquid asset reserves at 51.43% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Eyepoint Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Eyepoint Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
Vaxcyte Inc NASDAQ:PCVX	Biotechnology	41.54%
Bachem Holding AG SW:BANB	Biotechnology	0.00%
Definium Therapeutics, Inc. NASDAQ:DFTX	Biotechnology	38.51%
Chongqing Zhifei Bio Products SHE:300122	Biotechnology	-0.08%
HLB Co. Ltd KQ:028300	Biotechnology	3.29%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A SHG:688076	Biotechnology	2.30%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.12%

Annual Asset Resilience Ratio for Eyepoint Pharmaceuticals Inc (2009–2024)

The table below shows the annual Asset Resilience Ratio data for Eyepoint Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	64.81%	$271.21 Million	$418.46 Million	+50.79pp
2023-12-31	14.02%	$49.79 Million	$355.18 Million	-13.11pp
2022-12-31	27.13%	$48.93 Million	$180.36 Million	+14.61pp
2021-12-31	12.52%	$32.97 Million	$263.37 Million	--
2020-12-31	0.00%	$0.00	$91.72 Million	--
2017-12-31	0.00%	$0.00	$18.68 Million	--
2016-12-31	43.26%	$13.68 Million	$31.62 Million	+14.18pp
2015-12-31	29.09%	$9.41 Million	$32.37 Million	+16.10pp
2014-12-31	12.99%	$2.94 Million	$22.67 Million	-7.78pp
2013-12-31	20.76%	$3.37 Million	$16.25 Million	-27.52pp
2012-12-31	48.29%	$9.95 Million	$20.60 Million	+24.48pp
2011-12-31	23.81%	$11.22 Million	$47.11 Million	+19.04pp
2010-12-31	4.77%	$2.05 Million	$43.01 Million	-0.76pp
2009-12-31	5.53%	$2.05 Million	$37.10 Million	--

pp = percentage points

About Eyepoint Pharmaceuticals Inc

NASDAQ:EYPT USA Biotechnology

Market Cap

$285.62 Million

Market Cap Rank

#15143 Global

#3577 in USA

Share Price

$3.45

Change (1 day)

-5.74%

52-Week Range

$3.45 - $18.85

All Time High

$48.20